Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Cerebrolysin REGistry Study in Stroke A Registry Study to Assess Practices, Safety and Effectiveness of Cerebrolysin in Routine Treatment of Acute Ischemic Stroke

NCT02541227 is registered in ClinicalTrials.gov with Ever Neuro Pharma GmbH as lead sponsor.

NCT NCT02541227
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02541227 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Cerebrolysin REGistry Study in Stroke A Registry Study to Assess Practices, Safety and Effectiveness of Cerebrolysin in Routine Treatment of Acute Ischemic Stroke
Lead sponsor
Ever Neuro Pharma GmbH
Phase
Observational
Overall status
Terminated
Start date
May 31, 2014
Completion date
December 31, 2021
Enrollment
1,823 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

ischemic stroke